Synova portfolio company, Charnwood Molecular, a leading UK-based pre-clinical discovery CRO servicing the global pharmaceutical and biotechnology market, is pleased to announce the acquisition of biosciences specialist, Aurelia Bioscience.
The sector-leading expertise and technology development within Aurelia Bioscience will further expand Charnwood’s capabilities in the provision of world-class integrated drug discovery and development services. Charnwood is already a leading provider of medicinal and scale-up chemical development to the life sciences industry with a global customer base from biotech to large pharma. Aurelia will bring biology capabilities into the group allowing it to deliver holistic, integrated pre-clinical drug discovery programmes for its clients.
This acquisition follows the announcement in April this year when Charnwood committed to quadrupling its physical capacity through investment in state-of-the-art facilities at the Charnwood Campus Science Innovation and Technology Park in Loughborough. These market-leading laboratories will provide a gold-standard platform, enhancing the combined group’s ability to deliver exceptional services to its clients and supporting further growth in Charnwood’s team and capabilities.
